Equity Profile

CRNX

Crinetics Pharmaceuticals, Inc.

Health CarePharmaceuticals$3.7B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Crinetics Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for rare endocrine diseases and other serious conditions....

Key Metrics to Watch

EPS

Earnings per share will indicate the company's profitability and how it compares to analyst expectations, which is crucial for investor sentiment.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and growth trajectory, especially in the competitive pharmaceutical landscape.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRNX Q2-2026 Earnings Preview

Context

Company Snapshot

Crinetics Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for rare endocrine diseases and other serious conditions. With a market cap of $4 billion, its advancements in pharmaceuticals could significantly impact patient care and treatment options in the healthcare sector.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-3.44%

Avg Stock Reaction

+1.78%

Last Quarter Recap

In Q1-2026, Crinetics reported an EPS of -$1.23, slightly missing estimates but showing a smaller loss than expected. The stock reacted positively, gaining 4.27% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Crinetics' upcoming earnings, given the recent slight improvement in EPS surprises. However, the lack of analyst estimates adds uncertainty to the outlook.

Bull Case

If Crinetics can show improved revenue and a smaller loss than expected, it could signal strong demand for its products, driving stock prices higher.

Bear Case

Conversely, if the company reports a larger loss or disappointing revenue, it could lead to a sell-off, especially given the historical volatility in its stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS for Q2-2026?

The EPS figure will be critical in assessing the company's financial health and could significantly influence investor sentiment.

How does management plan to address the recent revenue trends?

Insight into revenue strategies will be essential for understanding the company's growth potential and market positioning.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Crinetics to improve its operational efficiency, which could lead to better-than-expected earnings.

Supporting Evidence

The company's recent history shows a tendency to surprise on the upside, even when expectations are low.

Options pricing suggests a significant move, indicating that traders are anticipating a shift in sentiment.

The lack of analyst estimates could mean that any positive news will have a more pronounced impact on the stock.

Key Risk

If the EPS comes in below -$1.20, it could challenge the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether Crinetics can stabilize its financial performance amid a competitive landscape.

Bull Confirmed If

A reported EPS loss of less than -$1.20 would confirm the bull case, suggesting improved operational efficiency.

Bear Confirmed If

An EPS loss greater than -$1.30 would confirm the bear case, indicating ongoing challenges in revenue generation.

Pre-Earnings Positioning

Options Market

Implied Move

±18.04%

Historical Avg

±2.9%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±17.7% while CRNX has averaged ±2.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

59.7%

Calls (600)P/C Ratio: 0.92Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Crinetics beats expectations, history suggests a potential stock increase of around +1.42%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further clarity from management.

Miss

A miss could lead to a decline around -1.90%, reflecting investor disappointment and concerns over the company's trajectory.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product approvals or pipeline developments.
2Management's commentary on cost management and operational efficiencies.
3Insights into market demand for Crinetics' products.
4Guidance on future revenue expectations and growth strategies.
5Responses to competitive pressures in the pharmaceutical industry.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Crinetics Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for rare endocrine diseases and other serious conditions....

Key Metrics to Watch

EPS

Earnings per share will indicate the company's profitability and how it compares to analyst expectations, which is crucial for investor sentiment.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and growth trajectory, especially in the competitive pharmaceutical landscape.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRNX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-3.44%

Avg Stock Reaction

+1.78%

Last Quarter Recap

In Q1-2026, Crinetics reported an EPS of -$1.23, slightly missing estimates but showing a smaller loss than expected. The stock reacted positively, gaining 4.27% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Crinetics' upcoming earnings, given the recent slight improvement in EPS surprises. However, the lack of analyst estimates adds uncertainty to the outlook.

Bull Case

If Crinetics can show improved revenue and a smaller loss than expected, it could signal strong demand for its products, driving stock prices higher.

Bear Case

Conversely, if the company reports a larger loss or disappointing revenue, it could lead to a sell-off, especially given the historical volatility in its stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS for Q2-2026?

The EPS figure will be critical in assessing the company's financial health and could significantly influence investor sentiment.

How does management plan to address the recent revenue trends?

Insight into revenue strategies will be essential for understanding the company's growth potential and market positioning.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Crinetics to improve its operational efficiency, which could lead to better-than-expected earnings.

Supporting Evidence

The company's recent history shows a tendency to surprise on the upside, even when expectations are low.

Options pricing suggests a significant move, indicating that traders are anticipating a shift in sentiment.

The lack of analyst estimates could mean that any positive news will have a more pronounced impact on the stock.

Key Risk

If the EPS comes in below -$1.20, it could challenge the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether Crinetics can stabilize its financial performance amid a competitive landscape.

Bull Confirmed If

A reported EPS loss of less than -$1.20 would confirm the bull case, suggesting improved operational efficiency.

Bear Confirmed If

An EPS loss greater than -$1.30 would confirm the bear case, indicating ongoing challenges in revenue generation.

Pre-Earnings Positioning

Options Market

Implied Move

±18.04%

Historical Avg

±2.9%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±17.7% while CRNX has averaged ±2.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

59.7%

Calls (600)P/C Ratio: 0.92Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Crinetics beats expectations, history suggests a potential stock increase of around +1.42%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further clarity from management.

Miss

A miss could lead to a decline around -1.90%, reflecting investor disappointment and concerns over the company's trajectory.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product approvals or pipeline developments.
2Management's commentary on cost management and operational efficiencies.
3Insights into market demand for Crinetics' products.
4Guidance on future revenue expectations and growth strategies.
5Responses to competitive pressures in the pharmaceutical industry.